On December 22, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Pfizer oral COVID-19 drug, Paxlovid. The medication treats mild-to-moderate COVID-19 in adults and children 12 years of age and older, who are at high risk for progression to severe COVID-19. Paxlovid requires a prescription and should be initiated after diagnosis of COVID-19 within 5 days of symptom onset. This medication is not authorized for the prevention of COVID-19.
On December 27, 2021, HHSC added the following Paxlovid national drug codes (NDC) to the Medicaid and Children’s Health Insurance Program (CHIP) formularies:
|Drug name||Dosage||Package size||NDC|
|Paxlovid EUA||300-100mg||6 tablets||00069-1085-06|
|Paxlovid EUA||300-100mg||30 tablets||00069-1085-30|
Paxlovid is nirmatrelvir tablets co-packaged with ritonavir tablets. The dosage for Paxlovid is 300mg of nirmatrelvir (two 150mg tablets) with 100mg of ritonavir (one 100mg tablet), with all three tablets taken together orally twice daily for 5 days.
There is no ingredient cost associated with the medication because the federal government has purchased treatment courses. The Texas Department of State Health Services (DSHS) will distribute the medication to pharmacies.
DSHS received a limited amount of quantities of Paxlovid. The initial plan is to allocate those to retail pharmacies, primarily through federal pharmacy partners. DSHS will expand to additional locations as the allocations progress and provide further information to providers and pharmacies on how to become a distribution site. Providers can find more information at the DSHS Therapeutics website, which includes a map of pharmacies where DSHS has distributed Paxlovid for the week of December 27, 2021, and an update on the recently-authorized therapeutics for COVID-19. DSHS will revise the site when they distribute additional allocations of Paxlovid in the coming weeks.